Zacks Research upgraded shares of Biogen (NASDAQ:BIIB – Free Report) from a strong sell rating to a hold rating in a research note released on Tuesday morning,Zacks.com reports. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Wall Street Zen upgraded Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Barclays increased their price target on Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Wednesday. Biogen Company Profile(Get Free Report)Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases.